AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein purchased 15,000 shares of the company's stock in a transaction on Thursday, November 5th. The stock was bought at an average cost of $6.90 per share, for a total transaction of $103,500.00. Following the acquisition, the director directly owned 40,000 shares of the company's stock, valued at $276,000. This represents a 60.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
AgomAb Therapeutics Stock Performance
Shares of AGMB traded up $0.67 during trading hours on Friday, hitting $7.64. 158,411 shares of the company were exchanged, compared to its average volume of 114,936. The firm has a fifty day simple moving average of $10.26 and a 200-day simple moving average of $11.86. AgomAb Therapeutics NV has a one year low of $6.46 and a one year high of $17.82.
AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, equities analysts predict that AgomAb Therapeutics NV will post -1.77 EPS for the current fiscal year.
Analyst Ratings Changes
AGMB has been the topic of several recent analyst reports. Johnson Rice restated a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an "overweight" rating and a $60.00 target price on the stock. HC Wainwright restated a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. Finally, Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an "overweight" rating for the company. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, AgomAb Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $37.50.
Get Our Latest Stock Report on AgomAb Therapeutics
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company's research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.
Agomab's lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn's disease, a condition in which scar tissue can narrow the intestine and contribute to complications.
The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
